ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

4-Morpholinopiperidine → Methyl 6-[(1-methylethyl)sulfonyl]-7-(methyloxy)-3-{[4-(4-morpholinyl)-1-piperidinyl]methyl}-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylate

HRID 245197
ノート
印刷プレビュー

反応式

HRID 245197 の反応式
Br[CH2:2][C:3]1[C:4]([C:25]2[CH:30]=[CH:29][CH:28]=[C:27]([C:31]([F:34])([F:33])[F:32])[CH:26]=2)=[N:5][C:6]2[C:11]([C:12]=1[C:13]([O:15][CH3:16])=[O:14])=[CH:10][C:9]([S:17]([CH:20]([CH3:22])[CH3:21])(=[O:19])=[O:18])=[C:8]([O:23][CH3:24])[CH:7]=2.[NH:35]1[CH2:40][CH2:39][CH:38]([N:41]2[CH2:46][CH2:45][O:44][CH2:43][CH2:42]2)[CH2:37][CH2:36]1>C(#N)C>[CH3:21][CH:20]([S:17]([C:9]1[CH:10]=[C:11]2[C:6](=[CH:7][C:8]=1[O:23][CH3:24])[N:5]=[C:4]([C:25]1[CH:30]=[CH:29][CH:28]=[C:27]([C:31]([F:33])([F:32])[F:34])[CH:26]=1)[C:3]([CH2:2][N:35]1[CH2:40][CH2:39][CH:38]([N:41]3[CH2:46][CH2:45][O:44][CH2:43][CH2:42]3)[CH2:37][CH2:36]1)=[C:12]2[C:13]([O:15][CH3:16])=[O:14])(=[O:19])=[O:18])[CH3:22]
参加物実験手順後処理出典と根拠反応ノート

参加物

4

反応物 2

HCID 7957244-MorpholinopiperidineHCID 67383678Methyl 3-(bromomethyl)-6-[(1-methylethyl)sulfonyl]-7-(methyloxy)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylate

生成物 1

HCID 67417230Methyl 6-[(1-methylethyl)sulfonyl]-7-(methyloxy)-3-{[4-(4-morpholinyl)-1-piperidinyl]methyl}-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylate収率 65%

試薬・触媒・溶媒 1

HCID 6342Acetonitrile溶媒

実験手順

A suspension of methyl 3-(bromomethyl)-6-[(1-methylethyl)sulfonyl]-7-(methyloxy)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylate (1.025 g, 1.83 mmol) and 4-(4-piperidinyl)morpholine (0.405 g, 2.379 mmol) in acetonitrile (10 mL) was stirred for 3 h. The solvent was removed under reduced pressure, and the residue was dissolved in DMSO and purified via HPLC (Biotage RP, 0-50% MeCN/H2O with 0.1% TFA). The fractions containing the product were neutralized with saturated aqueous NaHCO3 and extracted with methylene chloride (three times). The combined organic extracts were washed with brine (two times), dried over Na2SO4, filtered, and concentrated in vacuo to afford methyl 6-[(1-methylethyl)sulfonyl]-7-(methyloxy)-3-{[4-(4-morpholinyl)-1-piperidinyl]methyl}-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylate (0.77 g, 65% yield). 1H NMR (400 MHz, DMSO-d6) δ8.37 (s, 1H), 7.98 (s, 1H), 7.87-7.94 (m, 2H), 7.81 (s, 1H), 7.79 (d, J=7.78 Hz, 1H), 4.09 (s, 3H), 4.01 (s, 3H), 3.83 (quin, J=6.78 Hz, 1H), 3.61 (s, 2H), 3.53 (br. s., 4H), 2.59-2.69 (m, 2H), 2.38 (br. s., 4H), 2.00 (t, J=10.54 Hz, 1H), 1.77-1.86 (m, 2H), 1.62 (d, J=11.04 Hz, 2H), 1.24-1.30 (m, 2H), 1.22 (s, 3H), 1.21 (s, 3H); MS (m/z) 650.2 (M+H+).

後処理

  1. customThe solvent was removed under reduced pressure
  2. dissolutionthe residue was dissolved in DMSO
  3. custompurified via HPLC (Biotage RP, 0-50% MeCN/H2O with 0.1% TFA)
  4. additionThe fractions containing the product
  5. extractionextracted with methylene chloride (three times)
  6. washThe combined organic extracts were washed with brine (two times)
  7. dry with materialdried over Na2SO4
  8. filtrationfiltered
  9. concentrationconcentrated in vacuo

出典と根拠

ORDレコード
ord-d57ddee6f12d4277b0308ddb2b9ef57b
出典データセット
uspto-grants-2014_02
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08658636B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート